Update on
SARS-CoV-2 variant of concern Omicron

THE LATEST ON THE COVID-19 GLOBAL SITUATION
& SARS-CoV-2 VARIANT OF CONCERN OMICRON
Current global situation

CASES REPORTED TO WHO AS OF 13 JANUARY 2022 10h CET

- Cases: > 315 million
- Deaths: > 5.5 million

Cases depicted by bars; deaths depicted by line.

WHO Coronavirus Disease (COVID-19) Dashboard

* Cases depicted by bars; deaths depicted by line.

**Region of the Americas**  **Western Pacific Region**
**European Region**  **Eastern Mediterranean Region**
**African Region**  **South-East Asia Region**

Data smoothed with 7-day moving average.
Omicron has many key mutations compared to Delta

- On 26 November, WHO designated SARS-CoV-2 variant B.1.1.529 a variant of concern (VOC) and named it Omicron.
- Omicron has > 30 genetic mutations of the spike protein. The SARS-CoV-2 spike protein acts like a ‘key’ and allows the virus to bind to ACE-2 receptor and enter and infect cells in humans.
- The spike protein of SARS-CoV-2 is targeted by some currently approved COVID-19 vaccines; therefore, mutations in the spike protein need to be closely monitored.

Fig: Delta compared to Omicron with mutations in the S1 domain of the spike protein

Areas with mutations
- Red: More than 70%
- Orange: 40 to 70%
- Yellow: 15 to 40%
- Green: 5 to 15%
- Blue: 1 to 5%

Image: AFP

https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
Overall threat of Omicron depends on four key issues

1. **How transmissible the variant is**

2. **How well vaccines & prior infection protect against infection, transmission, disease and death**

3. **How virulent the variant is, compared to other variants**

4. **How well populations understand dynamics, perceive risk, and follow public health & social measures (PHSM)**

*Ability of Omicron to cause disease*
Omicron variant is now present in almost every country

Countries, territories and areas reporting Omicron COVID-19 variant of concern
(situation as of January 11, 2022, 4:00PM (CET))

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization
Map Production: WHO Health Emergencies Programme

Not applicable
Omicron is highly transmissible

• Omicron shows
  ➢ significant increase in growth rate;
  ➢ increased risk of a close contact becoming a secondary case; and
  ➢ increase in observed number of people infected by index case compared to Delta

• High growth rate likely due to a combination of factors including:
  ➢ immune evasion (virus evades the protective immune system) and
  ➢ potential intrinsic increased transmissibility

• Omicron has a clear growth advantage over Delta and is rapidly replacing other variants that are circulating in countries

Source:
Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States (who.int)
Omicron is rapidly replacing Delta everywhere, with faster replacement effects than ever seen before in the pandemic.

Estimated Omicron prevalence on 03 January 2022

Data downloaded from GISAID on 10 January 2022
Estimates shown for countries with at least 100 submitted sequences in last 60 days

Source:
Analysis by WHO HQ COVID-19 analytics team | Variant data downloaded from GISAID on 21 Dec 2021
Omicron shows preference for upper respiratory tract infection

- Omicron appears to show preference for infecting and replicating in the upper respiratory tract, compared to Delta and other strains which prefer the lower respiratory tract.
- This may confer a transmission advantage independent of immune evasion.
- Preliminary studies suggest that Omicron appears to have decreased ability to infect lung tissue, which may be a reason why people infected with Omicron have a less severe disease compared to Delta.
- Early studies from animal models show that Omicron-infected animals show fewer clinical signs and have less severe disease.
Omicron has reduced risk of hospitalization compared to Delta, suggest early studies from several countries including Denmark, South Africa, UK, Canada and the USA.

There is decoupling between case reports and hospitalization in places of high levels of population immunity.

Omicron infection appears to be associated with lower severity and lower proportion of hospitalized patients compared to previous variants, but the large number of people being infected with it translates into significant number of patients requiring hospital admission, putting strain on healthcare systems.
Routine diagnostics continue to detect Omicron

- Routinely used **diagnostic tests**, including PCR and antigen detection rapid diagnostic tests (Ag-RDT), continue to detect infection with Omicron
- Studies of the **comparative sensitivity of Ag-RDTs** are ongoing

Source:
Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States (who.int)
Omicron shows increased re-infection risk after previous SARS-CoV-2 infection

• There is evidence that Omicron has some **immune evasion**

• **Increased trend in re-infection** cases have been reported by some countries including South Africa, UK, Denmark, Israel

• The **risk of reinfection with the Omicron variant was estimated to be 5.4 fold higher** in comparison with the Delta variant in England, show UK studies

• **Significant reduction in antibody neutralization** with Omicron may contribute to increased risk of re-infection

Public health and safety measures such as: wearing a mask properly, keeping distance and washing hands regularly, continue to protect against infection by all SARS-CoV-2 variants

*Immune evasion refers to the ability of the virus to evade a person’s protective immune system

**Re-infection refers to infection after previous SARS-CoV-2 infection, while breakthrough infection refers to infection after vaccination.

***Test to detect levels of antibodies that bind the virus and prevent its infection

Source: Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States (who.int)
Preserved cellular immune process protects against severe disease

- **Protection through cellular immunity** appears to be preserved in Omicron infection.

- In those who have been previously infected, and/or previously vaccinated, **70-80% of certain cells involved in the protective immune process (CD4+ and CD8+) were maintained** for Omicron infection.

- This likely translates to **protection against severe disease and death after vaccination and after previous infection, remaining high**.

*Cellular immunity is a protective (non-antibody) immune process involving immune cells which kill virus-infected cells.*

Source: [Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States](https://www.who.int)
There are many studies underway that are looking at the effectiveness of COVID-19 vaccines and Omicron.

All initial vaccine effectiveness estimates show reduced effectiveness against infection and symptomatic disease than for Delta; However, estimates of protection remain high for severe end of disease spectrum.

This means that current COVID-19 vaccines are providing strong protection against severe disease and death if infected with all variants circulating, including Omicron.

Preliminary vaccine effectiveness estimates appear greater following booster than primary series for most products; no data on inactivated vaccines.

Unvaccinated cases were more likely to infect household members than those vaccinated or with previous infection. Booster doses further lowered of risk for household members.

Vaccine effectiveness refers to its ability to reduce disease.

** Studies from United Kingdom, Denmark, Canada and South Africa, vaccines studied were mRNA vaccines, AD26..COV2.S, and AstraZeneca Vaxzevria.

Source: Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States (who.int)
Therapeutics and Omicron

• **Interleukin-6 receptor blockers** and **corticosteroids** are expected to remain effective in the management of patients with severe and critical disease.

• Preliminary data from non-peer reviewed publications suggest that **some of the monoclonal antibodies developed against SARS-CoV-2** may have impaired **neutralization** against Omicron.
Older people and those with underlying conditions remain at risk

- Older people continue to be at greater risk for developing severe disease
- Those with underlying conditions, of any age, are also at risk for developing severe disease

People at greater risk of COVID-19 include those: unvaccinated, with obesity, people over the age of 60, hypertension, Diabetes mellitus, cardiac disease, chronic lung disease, cerebrovascular disease, dementia, mental disorders, chronic kidney disease, immunosuppression, cancer, HIV/AIDS, pregnancy.
Settings with higher risk of contracting COVID-19

- The following settings increase the risk of contracting COVID-19 and **should be avoided**:  
  - Closed spaces with poor ventilation  
  - Crowded areas with many people around  
  - Close contact with others, such as close-range conversations
Priority actions for Member States: surveillance, testing and vaccination

- Report all initial cases/clusters associated with Omicron variant infection to WHO through the International Health Regulations (IHR) mechanism
- Report (publicly or through IHR) the weekly relative prevalence of Omicron
- Intensify COVID-19 vaccination coverage in at-risk and particular high priority populations
- Implement comprehensive, multi-layered and targeted use of public health and social measures (PHSM) to reduce the spread of all variants of SARS-CoV-2

Source: Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States (who.int)
Actions for Member States: clinical management, travel and updated national plans for surge

• **Administer clinical care of patients with COVID-19** infected with any SARS-CoV-2 variant; according to evidence-based guidelines, such as the [WHO living guidelines for clinical management and therapeutics](https://www.who.int); adapted appropriately for local context and resource settings

• **Follow a risk-based approach** to adjust international travel measures in a timely manner is recommended

• Blanket travel bans will not prevent international spread of any SARS-CoV-2 variants of concern, including Omicron; and can place a heavy burden on lives and livelihoods

• **Regularly reassess and revise national plans** based on current situation and capacities

• **Ensure mitigation plans and surge capacity are in place** to maintain essential health services

*Source:* *Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States* (who.int)
Preventive measures effectively reduce the risk of COVID-19, including Delta and Omicron.

- Stay at home if you feel unwell
- Keep a physical distance of at least 1 metre from others
- Open windows to improve ventilation
- Cough or sneeze into a bent elbow or tissue
- Wash hands frequently
- When indoors, avoid crowded or poorly ventilated areas
- Wear a well-fitting mask

Preventive measures continue to be effective and should continue to be implemented to reduce the spread of COVID-19.
## Characteristics of Delta and Omicron

<table>
<thead>
<tr>
<th></th>
<th>Delta</th>
<th>Omicron</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Transmissibility</strong></td>
<td>Increased transmissibility compared to wild-type SARS-CoV-2, Variants of Interest (VOIs) and Variants of Concern (VOCs) Alpha, Delta and Gamma.</td>
<td>Increased growth rate as compared to Delta because of intrinsic characteristics of Omicron and immune escape.</td>
</tr>
<tr>
<td><strong>Disease severity</strong></td>
<td>Possible Increased risk of hospitalization as compared to early pandemic SARS-CoV-2 and other VOCs.</td>
<td>Reduced risk of hospitalization compared to Delta; upper respiratory tract infection compared with lower respiratory tract infection by Delta.</td>
</tr>
<tr>
<td><strong>Risk of reinfection</strong></td>
<td>Reduction in antibody neutralizing activity reported.</td>
<td>Reduced antibody neutralizing activity reported; increased risk of reinfection.</td>
</tr>
<tr>
<td><strong>Impact on diagnostics</strong></td>
<td>None reported to date.</td>
<td>RT PCR and Ag RDTs continue to detect Omicron. Studies on Ag RDT sensitivity are ongoing.</td>
</tr>
<tr>
<td><strong>Impact on therapeutics</strong></td>
<td>None reported to date.</td>
<td>No impact on effectiveness of corticosteroids and IL-6 blockers; Reduced effectiveness of some monoclonal antibodies; limited evidence.</td>
</tr>
<tr>
<td><strong>Effectiveness of COVID-19 vaccines</strong></td>
<td>Protection retained against severe disease; possible reduced protection against symptomatic disease and infection; limited evidence.</td>
<td>Reduced protection against symptomatic disease and infection; booster doses increase vaccine effectiveness; limited and non-peer reviewed evidence.</td>
</tr>
</tbody>
</table>

[https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states)
Summary

- **Omicron is highly transmissible** and is rapidly replacing Delta as the dominant SARS-CoV-2 variant.
- Omicron appears to show **preference for infecting the upper respiratory tract**, unlike other SARS-CoV-2 variants of concern.
- There is increasing evidence of **immune evasion** as Omicron shows increased risk of both re-infection and breakthrough infection after vaccination.
- Vaccines protect against hospitalization but are **less effective against Omicron symptomatic disease**; and booster doses increase vaccine effectiveness.
- In places with high population immunity, Omicron also appears to have a **reduced risk of severe disease and hospitalizations**.
- Higher incidence of cases and milder infection with Omicron has led to a decoupling of cases and hospitalization rates, but there are significant numbers of hospitalized patients as a result of the high levels of transmission.
- Older persons and those with underlying conditions continue to be at high risk of severe disease.
- Measures such as wearing a well-fitting mask properly, keeping physical distance and other public health and social measures continue to protect against all SARS-CoV-2 variants.
Additional resources

- **Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States**

- **Tracking SARS-CoV-2 variants**
  [https://www.who.int/activities/tracking-SARS-CoV-2-variants](https://www.who.int/activities/tracking-SARS-CoV-2-variants)

- **COVID-19 weekly epidemiological update & weekly operational update**

- **www.gisaid.org**
  The GISAID Initiative promotes the rapid sharing of data from all influenza viruses and the coronavirus causing COVID-19
  [https://www.gisaid.org/](https://www.gisaid.org/)

- **Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern (who.int)**

- **WHO issues best practices for naming new human infectious diseases**
COVID-19 protective measures

Protect yourself & others

- Keep your distance
- Wash your hands frequently
- Cough & sneeze into your elbow
- Ventilate or open windows
- Wear a mask
- Get vaccinated
We are #InThisTogether against COVID-19